Recent News

• 04.07.2025 - 24th Annual Needham Virtual Healthcare Conference
• 04.01.2025 - Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
• 04.01.2025 - Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
• 03.27.2025 - Clearside Biomedical Q4 2024 Financial Results and Corporate Update Call
• 03.27.2025 - Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.27.2025 - Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.24.2025 - Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
• 03.24.2025 - Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
• 03.20.2025 - Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
• 03.20.2025 - Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Recent Filings

• 04.01.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.04.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities